Institutional investors own a significant stake of 43 percent in MiMedx Group, Inc.
MDXG Stock | USD 8.40 0.26 3.19% |
Roughly 62% of all MiMedx's stockholders are looking to take a long position. The analysis of the overall investor sentiment regarding MiMedx Group suggests that some traders are interested. The current market sentiment, together with MiMedx's historical and current headlines, can help investors time the market. In addition, many technical investors use MiMedx Group stock news signals to limit their universe of possible portfolio assets.
MiMedx |
Key Insights Institutions substantial holdings in MiMedx Group implies that they have significant influence over the...
Read at finance.yahoo.com
![]() |
MiMedx Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards MiMedx can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
MiMedx Fundamental Analysis
We analyze MiMedx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MiMedx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MiMedx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
MiMedx is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
MiMedx Group Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MiMedx stock to make a market-neutral strategy. Peer analysis of MiMedx could also be used in its relative valuation, which is a method of valuing MiMedx by comparing valuation metrics with similar companies.
Peers
MiMedx Related Equities
HOWL | Werewolf Therapeutics | 6.90 | ||||
ERAS | Erasca | 6.20 | ||||
CCCC | C4 Therapeutics | 4.23 | ||||
GPCR | Structure Therapeutics | 4.08 | ||||
DSGN | Design Therapeutics | 3.85 | ||||
PTGX | Protagonist Therapeutics | 3.44 | ||||
CNTA | Centessa Pharmaceuticals | 3.25 | ||||
CVKD | Cadrenal Therapeutics, | 3.20 | ||||
ZNTL | Zentalis Pharmaceuticals | 2.48 | ||||
SNDX | Syndax Pharmaceuticals | 2.36 | ||||
IPSC | Century Therapeutics | 1.49 | ||||
GLUE | Monte Rosa | 0.92 | ||||
KROS | Keros Therapeutics | 0.64 | ||||
NVCT | Nuvectis Pharma | 0.30 | ||||
EWTX | Edgewise Therapeutics | 0.83 | ||||
INZY | Inozyme Pharma | 0.83 | ||||
CGEM | Cullinan Oncology | 1.39 | ||||
STOK | Stoke Therapeutics | 1.75 | ||||
IKNA | Ikena Oncology | 2.19 | ||||
DAWN | Day One | 4.03 | ||||
MLYS | Mineralys Therapeutics, | 8.23 |
Complementary Tools for MiMedx Stock analysis
When running MiMedx's price analysis, check to measure MiMedx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MiMedx is operating at the current time. Most of MiMedx's value examination focuses on studying past and present price action to predict the probability of MiMedx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MiMedx's price. Additionally, you may evaluate how the addition of MiMedx to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |